Exploring how the genome can improve cancer immunotherapy
Official title: Harnessing the repetitive genome for cancer immunotherapy
Funded at Dana-Farber Cancer Inst · NIH-10894129 · Data updated 2026-11-12
This study is exploring how certain parts of our DNA can help improve cancer treatments by boosting the immune system's ability to fight tumors, and it's designed to benefit patients looking for better options in their cancer care.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $268,752 |
| NIH project number | 5K08CA267065-02 |
| Project ID | NIH-10894129 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with various types of cancer who may benefit from innovative immunotherapy approaches.
✕Less likely to help
Patients with non-cancerous conditions or those not eligible for immunotherapy may not receive benefits from this research.
What this research studies
This research focuses on understanding the role of the repetitive genome in cancer and how it can be harnessed to enhance immunotherapy treatments. Led by Dr. Gabriel Griffin, the project aims to investigate the basic mechanisms of immune regulation in cancer, particularly through the study of transposable elements and genome topology. Patients may benefit from advancements in cancer treatment as the research seeks to uncover new strategies for improving immune responses against tumors. The project is part of a five-year training program that combines laboratory work with mentorship from leading experts in cancer biology.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies that better harness the body's immune system to fight cancer.
How similar studies have gone: Other research in cancer epigenetics and immunotherapy has shown promising results, indicating that this approach has the potential for significant breakthroughs.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Griffin, Gabriel K. — Dana-Farber Cancer Inst
- Study coordinator: Griffin, Gabriel K.
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.